Repurposing Anti‐diabetic GLP‐1 Receptor Agonists for the Treatment of Alzheimer's Disease

The GLP-1 RAs exhibit neuroprotective mechanisms through anti-inflammatory actions, enhancing synaptic function and reducing amyloid plaque formation. These findings warrant further clinical trials to establish their efficacy and safety in humans. The comparison of in vivo studies highlights the positive impact of GLP-1 RAs on cognition, learning, memory, and reducing AD pathology, suggesting their potential as first-line treatments for AD patients.